期刊文献+

老年与非老年组多发性骨髓瘤患者的血清TRacp-5b及IL-6水平分析 被引量:2

Serum TRacp-5b and IL-6 levels in elderly and vs elderly patients with multiple myeloma
下载PDF
导出
摘要 目的:对老年与非老年组多发性骨髓瘤患者的血清TRacp-5b及IL-6水平进行分析。方法:2011年3月至2015年3月本院收治50例多发性骨髓瘤患者按年龄分为老年组与非老年组(老年组26例非老年组24例),选取健康献血员血清30份作为对照组,所有对照组及患者采用酶联免疫吸附测试法进行血清血清抗酒石酸酸性磷酸酶(TRacp-5b)及白介素6(IL-6)水平水平测试。对两组患者的结果及疾病的发生、转归及预后进行分析。结果:50例患者平均血清TRacp-5b水平为5.6±0.5U/L,IL-6水平为109.62±0.5pg/ml。远高于30例对照组水平(2.8±0.5 U/L及41.25±0.5pg/ml(P<0.05)。老年组TRacp-5b及IL-6水平分别为6.8±0.5 U/L及159.45±0.5 pg/ml,非老年组TRacp-5b及IL-6水平分别为5.1±0.5U/L及91.25±0.5pg/m。两组患者的TRacp-5b水平及IL-6水平老年组患者均明显高于非老年组(P<0.05)。结论:多发性骨髓瘤患者血清TRacp-5b及IL-6水平均远高于正常健康献血员(P<0.05),老年组患者血清TRacp-5b及IL-6水平远高于非老年组患者(P<0.05),TRacp-5b及IL-6水平的检测对于疾病的早期治疗及预后分析具有较高价值。 Objective:To investigate the serum TRacp-5b and IL-6 levels in elderly and vs elderly patients with multiple myeloma.Methods:Fifty patients with multiple myeloma were were divided into the elderly group (n=26)and non-elderly group (n=24)according to patient age. Thirty serum samples from healthy blood donors were used as control group. The control sera and patient serum samples were measured for tartrate-resistant acid phosphatase (TRacp-5b ) and interleukin-6 (IL-6 ) levels by using enzyme-linked immunosorbent assay (ELISA). The test results,occurrence and outcomes of multiple myeloma in the two groups were analyzed. Results:In the 50 patients,the mean serum levels of TRacp-5b and IL-6 were 5. 6U/L and 109. 62pg/ml, respectively,which were much higher than those in 30 samples of the control group (2.8 U/L and 41.25 pg/ml,nbsp;P〈0.05). The mean serum levels of TRacp-5b and IL-6 were 6.8 U/L and 159.45 pg/ml in the elderly group, compared with 5.1 U/L and 91.25pg/m in the non-elderly group. The serum levels of TRacp-5b and IL-6 in the elderly patients were significantly higher than in the non-elderly patients (P〈0.05). Conclusion:The serum levels of TRacp-5b and IL-6 levels are much higher in multiple myeloma patients than in normal healthy blood donors (P〈0.05),and in elderly patients than in non-elderly patients (P〈0.05). Measurement of TRacp-5b and IL-6 levels may be of high value for early treatment and prognosis of multiple myeloma.
出处 《广州医科大学学报》 2016年第4期68-70,共3页 Academic Journal of Guangzhou Medical University
关键词 多发性骨髓瘤 抗酒石酸酸性磷酸酶 白介素6 年龄 Multiplemyeloma tartrate-resistantacidphosphatase age
  • 相关文献

参考文献5

二级参考文献30

  • 1李守静,李宏然,赵相印,李清朗.多发性骨髓瘤诊断的探讨(附2547例分析)[J].中华肿瘤杂志,1995,17(1):43-46. 被引量:151
  • 2武永吉 张安.骨髓瘤前期2例[J].中华内科杂志,1992,31:545-546. 被引量:1
  • 3Greipp P, Facon T, Williams CD, et al. A single subcutaneous dose of an osteoprotegerin ( OPG ) construct ( AMGN-0007 ) causes a profound and sustained decrease in bone resorption comparable to standard intravenous bisphosphonate in patients with multiple myeloma. Blood,2001,98 : 775a. 被引量:1
  • 4Oyajobi BO, Franchin G', Williams PJ, et al. Dual effects of macrophage inflammatory protein-1 alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood, 2003,102 : 311-319. 被引量:1
  • 5Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1 alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res, 2005,65:1700-1709. 被引量:1
  • 6Heider U, Fleissner C, Zavrski I, et al. Bone markers in multiple myeloma. Eur J Cancer,2006,42:1544-1553. 被引量:1
  • 7Tian E, Zhan F, Walker R, et al. The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med, 2003, 349 : 2483-2494. 被引量:1
  • 8Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 2005,106:3160-3165. 被引量:1
  • 9Oyajobi BO, Garrett IR, Gupta A, et al. Role of Dickkopf 1 (DKK) in myeloma bone disease and modulation by the proteasome inhibitor Velcade. 26th annual meeting of the American Society of Bone and Mineral Research. Seattle WA, 2004:1011. 被引量:1
  • 10Mukherjee S, Raje N, Patel C, et al. Bortezomib induces proliferation of mesenchymal progenitor cells and promotes differentiation towards osteoblastic lineage. Blood,2006,108:88. 被引量:1

共引文献85

同被引文献24

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部